International Journal of Cardiology
Volume 135, Issue 3 , Pages 399-401 , 10 July 2009

Should statins be given routinely in all coronary patients?

Received 6 February 2008 ,Accepted 10 May 2008.

References 

  1. Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol. 2008;135:128–130
  2. Rallidis LS, Lekakis J, Kremastinos DT. Current questions regarding the use of statins in patients with coronary heart disease. Int J Cardiol. 2007;122:188–194
  3. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  4. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER study group PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–1630
  5. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol. 2005;23:8606–8612
  6. Boudreau DM, Yu O, Miglioretti DL, Buist DS, Heckbert SR, Daling JR. Statin use and breast cancer risk in a large population-based setting. Cancer Epidemiol Biochem Prev. 2007;16:416–421
  7. Pocobelli G, Newcomb PA, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Egan KM. Statin use and risk of breast cancer. Cancer. 2008;112:27–33
  8. Baigent C, Keech A, Keamey PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  9. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA. 2006;295:74–80
  10. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007;120:833–843
  11. Strandberg TE, Pyorala K, Cook TJ, et al. 4S Group. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet. 2004;364:771–777
  12. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357:1477–1486
  13. Hindler K, Cleeland CS, Rivera E, Collard CD. The role of statins in cancer therapy. Oncologist. 2006;11:306–315
  14. Hoque A, Chen H, Xu XC. Statin induces apoptosis and cell growth arrest in prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2008;17:88–94
  15. Wali VB, Sylvester PW. Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids. 2007;42:1113–1123
  16. Taras D, Blanc JF, Rullier A, et al. Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. J Hepatol. 2007;46:69–76
  17. Poynter JN, Gruber SB, Higgins PDR, et al. Statins and the risk of colorectal cancer. N Engl J Med. 2005;352:2184–2192
  18. Farwell WR, Scranton RE, Lawler EV, et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008;100:134–139
  19. Flick ED, Habel LA, Chan KA, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007;16:2218–2225
  20. Khurana V, Bejjanki HR, Caldito G, Owens MW. Statins reduce the risk of lung cancer in humans: a large case–control study of US veterans. Chest. 2007;131:1282–1288
  21. Khurana V, Sheth A, Caldito G, Barkin JS. Statins reduce the risk of pancreatic cancer in humans: a case–control study of half a million veterans. Pancreas. 2007;34:260–265
  22. Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007;30:515–525
  23. Grundy SM, Cleeman JI, Menz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  24. Rallidis LS, Zolindaki MG, Chatziioakimidis VK, Velissaridou AH, Konstantellou ES, Papasteriadis EG. High prevalence and suboptimal treatment of risk factors in Greek coronary patients. Acta Cardiol. 2001;56:7–15
  25. Rallidis LS, Vavoulis P, Varounis C, et al. Suboptimal treatment of low density lipoprotein cholesterol in very high risk patients with stable coronary heart disease. Atherosclerosis (Suppl) 2008;9:238.
  26. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20536 high-risk individuals: a randomized placebo controlled trial. Lancet. 2002;360:7–22
  27. Pitt B. Low-density lipoprotein in patients with stable coronary heart disease. Is it time to shift our goals?. N Engl J Med. 2005;352:1483–1484

PII: S0167-5273(08)00417-8

doi: 10.1016/j.ijcard.2008.05.001

International Journal of Cardiology
Volume 135, Issue 3 , Pages 399-401 , 10 July 2009

Article Tools